Stay updated with breaking news from Skye Bioscience. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Skye Bioscience, Inc. (OTCMKTS:SKYE – Get Free Report) was the target of a large growth in short interest in the month of July. As of July 31st, there was short interest totalling 45,100 shares, a growth of 14.2% from the July 15th total of 39,500 shares. Based on an average trading volume of 2,376,800 shares, […]
Skye Bioscience, Inc. (OTCMKTS:SKYE – Get Free Report) was the target of a large decline in short interest in June. As of June 30th, there was short interest totalling 24,200 shares, a decline of 80.3% from the June 15th total of 123,100 shares. Based on an average trading volume of 2,567,100 shares, the short-interest ratio […]
(2023-07-06 | OTCQB:SKYE) Skye Bioscience Completes Production and Filling of Investigational Drug Material in Preparation for Phase 2a Glaucoma Clinical Trial
Skye Bioscience, Inc. SKYE, a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma and ocular hypertension,…
Skye Bioscience, Inc. (OTCQB: SKYE), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma and ocular hypertension, announced that its contract manufacturer, NextPharma Oy, in Finland, has completed production of placebo and